semaglutide and kidney disease FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in Add-On, Not Replacement: Semaglutide's Role

(1992) Serum and salivary magnesium levels in migraine and tension-type headache

By design, these medications slow stomach emptying

Patients with RA should continue evidence-based DMARD therapy as recommended by the American College of Rheumatology, while any GLP-1 use should be reserved for approved indications such as diabetes or weight management under appropriate medical supervision

[36] Since July 2018, Novo Nordisk has spent approximately $884 million to promote its pharmaceutical products on TV advertisements alone

You may face higher risk if any of these apply: Older age, or existing hearing loss Reduced kidney function Taking several ototoxic medications at once Long treatment courses or high doses Frequent exposure to loud noise If any of these fit, ask about a baseline hearing test before you start